Literature DB >> 7529917

Catalytic activity and transformation potential of v-Src require arginine 385 in the substrate binding pocket.

M Senften1, G Schenker, J M Sowadski, K Ballmer-Hofer.   

Abstract

Tyrosine kinase are important mediators of signal transduction in eukaryotic cells. In order to better understand the mechanism of catalysis we studied a set of mutants of the prototype tyrosine kinase, the c-Src protein, a homologue of the Rous Sarcoma virus oncogene. Based on an X-ray structure of cAMP-dependent protein kinase (cAPK) we mutated an arginine residue conserved in subdomain VI of all known kinases to a non-charged residue. This residue coordinates phosphate of the autophosphorylation site located in subdomain VII of cAPK and this interaction has been proposed to be crucial for substrate binding. The mutant R385A of c-Src had low kinase activity towards exogenous substrates yet was able to autophosphorylate at tyrosine 416. When introduced into an activated v-src gene the R385A mutation totally blocked cell transformation. Our data suggest that the function of the conserved arginine 385 is to coordinate the phosphate of the autophosphorylation site and to provide in this way a stable template for substrate binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529917

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Two adaptor proteins differentially modulate the phosphorylation and biophysics of Kv1.3 ion channel by SRC kinase.

Authors:  Karen K Cook; Debra A Fadool
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

2.  Structural versatility that serves the function of the HRD motif in the catalytic loop of protein tyrosine kinase, Src.

Authors:  Yixin Cui; Gongqin Sun
Journal:  Protein Sci       Date:  2018-12-30       Impact factor: 6.725

3.  Mutations in the catalytic loop HRD motif alter the activity and function of Drosophila Src64.

Authors:  Taylor C Strong; Gurvinder Kaur; Jeffrey H Thomas
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.